Skip to main content

Table 3 Meta-analysis of the HIF-1α G1790A polymorphism and cancer risk

From: Association between HIF-1α C1772T/G1790A polymorphisms and cancer susceptibility: an updated systematic review and meta-analysis based on 40 case-control studies

Variables    AA vs.GG GA vs. GG AA + AG vs.GG AA vs.GA + GG A vs.G
Study Case/control I 2 Phet OR (95% CI) Case/control I 2 Phet OR (95% CI) Case/control I 2 Phet OR (95% CI) Case/control I 2 Phet OR (95% CI) Case/control I 2 Phet OR (95% CI)
Overall 30 6538/9948 57 0.01 5.11 (2.08-12.56)* 7005/10442 77 <0.001 1.45 (1.05-1.99)* 7117/10442 83 <0.001 1.63 (1.16-2.30)* 7117/10442 58 0.01 4.41 (1.80-10.84)* 14234/20884 86 <0.001 1.77 (1.23-2.25)*
Overall in HWE 29 6449/9699 61 0.003 5.14 (1.67-15.86)* 6873/10138 69 <0.001 1.35 (1.01-1.81)* 6971/10154 79 <0.001 1.53 (1.10-2.12)* 6971/10154 60 0.004 4.80 (1.58-14.55)* 13942/20308 85 <0.001 1.70 (1.17-2.46)*
Cancer type
Breast 4 623/501 0 0.34 1.44 (0.38-5.44) 692/550 53 0.12 1.03 (0.70-1.52) 698/553 60 0.08 1.05 (0.72-1.53) 698/553 0 0.36 1.41 (0.37-5.40) 1396/1466 65 0.56 1.07 (0.76-1.52)
Cervical 3 708/819 0 0.99 0.35 (0.04-3.39) 740/871 57 0.13 0.62 (0.40-0.98) 740/837 51 0.15 0.60 (0.38-0.94) 740/837 0 0.99 0.36 (0.04-3.450 1480/1746 42 0.19 0.59 (0.38-0.91)
Oral 4 517/633 75 0.02 72.11 (2.08-2502.44)* 542/670 70 0.02 3.17 (1.26-7.92)* 583/670 92 <0.001 7.92 (1.58-39.64)* 583/670 75 0.02 58.05 (1.70-1985.77)* 1166/1340 96 0.01 9.66 (1.31-71.15)*
Prostate 3 1866/2230 - - - 1927/2280 1 0.37 1.42 (0.97-2.07) 1928/2280 7 0.34 1.44 (0.98-2.10) 1928/2280 - - - 3856/4560 10 0.33 1.45 (0.99-2.11)
Renal 4 1016/1267 0 0.95 5.10 (2.21-11.73) 1123/1354 92 <0.001 1.51 (0.45-5.05)* 1139/1364 92 <0.001 1.58 (0.49-5.04)* 1139/1364 0 0.76 3.09 (1.38-6.92) 2278/2728 89 <0.001 1.53 (0.60-3.92)*
Renal in HWE 3 937/1018 - - - 991/1076 0 0.42 1.00 (0.69-1.47) 993/1076 0 0.6 1.04 (0.71-1.52) 993/1076 - - - 1986/2152 0 0.78 1.07 (0.74-1.55)
Lung 3 405/481 0 0.87 5.42 (2.74-10.70) 466/555 0 0.57 1.72 (1.22-2.41) 509/566 0 0.46 2.14 (1.56-2.94) 509/566 0 0.79 4.52 (2.31-8.83) 1018/1132 0 0.48 2.27 (1.74-2.95)
Colorectal 2 545/2327 - - - 554/2336 - - - 554/2336 0 0.45 0.97 (0.57-1.63) 554/2336 - - - 1108/4672 - - -
Pancreatic 2 255/391 - - - 319/423 82 0.02 1.61 (0.24-10.76)* 322/423 63 0.1 3.14 (1.99-4.97) 322/423 - - - 644/846 0 0.42 3.08 (1.98-4.78)
Other 7 593/1377 - - - 642/1377 74 <0.001 1.53 (0.65-3.59)* 644/1377 72 <0.001 1.57 (0.70-3.53)* 644/1377 - - - 1288/2754 69 0.01 1.57 (0.75-3.30)*
Ethnicity
Asian 15 3607/4263 13 0.33 3.50 (2.05-5.98) 4010/4614 74 <0.001 1.44 (1.04-1.99)* 4063/4630 76 <0.001 1.49 (1.07-2.08)* 4063/4630 0 0.45 3.12 (1.83-5.32) 8126/9260 77 <0.001 1.49 (1.08-2.05)*
Caucasian 13 1829/4357 0 0.69 6.63 (3.11-14.12) 1926/4450 81 <0.001 1.36 (0.58-3.19)* 1948/4460 82 <0.001 1.45 (0.69-3.04)* 1948/4460 0 0.49 4.21 (2.04-8.71) 3896/8920 75 <0.001 1.65 (0.84-3.24)*
Caucasian in HWE 12 1750/4108 0 0.74 12.40 (2.19-70.22) 1794/4172 68 0.01 1.10 (0.48-2.49)* 1802/4172 67 0.01 1.22 (0.62-2.37)* 1802/4172 0 0.79 11.37 (2.02-63.93) 3604/8344 68 0.01 1.65 (1.17-2.32)*
Source of control
HB 13 3197/3945 45 0.12 1.54 (0.35-6.70) 3510/4234 77 <0.001 1.37 (0.92-2.05)* 3554/4248 79 <0.001 1.40 (0.93-2.11)* 3554/4248 35 0.19 3.13 (1.74-5.62) 7108/8496 79 <0.001 1.38 (0.93-2.05)*
PB 17 3133/5705 66 0.01 11.55 (6.62-20.12)* 3295/5882 78 <0.001 1.51 (0.88-2.58)* 3563/6194 85 <0.001 1.90 (1.06-3.39)* 3563/6194 69 0.002 10.27 (2.42-43.63)* 6726/11788 89 <0.001 2.25 (1.18-4.29)*
PB in HWE 16 3054/5456 67 0.006 15.51 (2.53-94.94)* 3163/5604 60 0.01 1.34 (0.85-2.11)* 3417/5906 81 <0.001 1.71 (0.97-3.03)* 3417/5906 66 0.007 14.20 (2.38-84.61)* 6434/11212 89 <0.001 2.33 (1.91-2.84)*
  1. HWE: Hardy-Weinberg Equilibrium; PB: population based; HB: hospital based; Phet: P value for heterogeneity. *Random-effects model was used when P value for heterogeneity test <0.05; otherwise, fixed-effects model was used.